Zelgen(SH:688266)2021-10-26 16:00Revenue and Profitability - The company's operating revenue for Q3 2021 was ¥56,169,069.51, representing a year-over-year increase of 100.76%[7] - Year-to-date revenue reached ¥98,578,591.59, showing a significant increase of 252.34% compared to the same period last year[7] - The net profit attributable to shareholders was -¥115,702,656.87 for the quarter, with a year-to-date net profit of -¥292,672,771.57[7] - Total operating revenue for the first three quarters of 2021 reached ¥98,578,591.59, a significant increase from ¥27,978,335.84 in the same period of 2020, representing a growth of approximately 253%[38] - The net loss attributable to shareholders for the third quarter of 2021 was ¥292,672,771.57, compared to a loss of ¥228,372,245.34 in the same quarter of 2020[41] - The company reported a total profit loss of ¥310,845,579.98 for the third quarter of 2021, compared to a loss of ¥203,726,480.07 in the same quarter of 2020[41] Research and Development - Research and development (R&D) expenses totaled ¥139,571,000.92 for the quarter, an increase of 50.59% year-over-year[11] - R&D expenses accounted for 248.48% of operating revenue in Q3 2021, a decrease of 82.78 percentage points compared to the previous year[11] - Research and development expenses for the first three quarters of 2021 were ¥337,082,287.48, up from ¥222,024,375.43 in 2020, reflecting a growth of approximately 52%[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,851,624,622.40, down 6.02% from the previous year[11] - The total current assets decreased to ¥1,527,201,808.79 from ¥1,669,567,723.00 in the previous year[33] - The company's inventory increased significantly to ¥48,798,341.42 from ¥23,137,763.14 year-over-year[33] - The total liabilities as of the reporting date were ¥446,064,017.62, an increase from ¥278,692,214.57 in the previous year, representing a growth of about 60%[36] - The total equity attributable to shareholders decreased to ¥1,347,663,760.81 from ¥1,617,725,382.28 year-over-year, indicating a decline of approximately 17%[38] - The total non-current liabilities increased to ¥164,922,851.45 from ¥137,815,096.70, reflecting a growth of approximately 20%[36] Cash Flow - The company reported a net cash flow from operating activities of -¥328,639,988.58 year-to-date[11] - Cash inflows from operating activities totaled 119,775,624.60 CNY, a substantial increase from 45,525,184.59 CNY year-over-year[48] - Cash outflows from operating activities amounted to 448,415,613.18 CNY, compared to 269,056,510.32 CNY in the previous year, leading to a net cash flow from operating activities of -328,639,988.58 CNY[48] - The net cash flow from investment activities was 243,336,370.65 CNY, a significant recovery from -543,158,534.96 CNY in the previous year[48] - The net cash flow from financing activities was 91,688,238.96 CNY, compared to 1,859,065,393.34 CNY in the same period last year, indicating a decrease in financing activities[50] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,754, with the largest shareholder Zelin Sheng holding 49,636,620 shares, representing 20.68%[20] - The top ten shareholders hold a total of 100,000,000 shares, representing a significant portion of the company's equity[20] - The company has no reported related party transactions or agreements among the top shareholders, except for Zelin Sheng and Lu Huiping being identified as acting in concert[28] Other Information - The company began commercial sales of its drugs in June 2021, contributing to the significant increase in revenue[16] - The company has not reported any new product developments or market expansion strategies in the current quarter[29] - The company has implemented new leasing standards effective January 1, 2021, which are not expected to have a significant impact on financial statements[58]